A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Status Not yet recruiting

Clinical Trial Summary

The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Clinical Trial Description

Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets. In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04660617
Study type	Observational [Patient Registry]
Source	West China Hospital
Contact	Jinge Zhao, Dr.
Phone	86 13679017572
Email	jingezhao@foxmail.com
Status	Not yet recruiting
Phase
Start date	August 1, 2021
Completion date	April 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Suspended	`NCT05361915` - Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer	Phase 2
Recruiting	`NCT05067140` - A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer	Phase 1/Phase 2
Completed	`NCT03646162` - Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer	Phase 2
Active, not recruiting	`NCT03413995` - Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations	Phase 2
Not yet recruiting	`NCT06461689` - Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
Recruiting	`NCT05078151` - Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer	N/A
Recruiting	`NCT03507595` - Evaluation of the Metastasis and Recurrence of Prostate Cancer
Completed	`NCT03362359` - Ga-68-PSMA-11 in High-risk Prostate Cancer	Phase 1/Phase 2
Recruiting	`NCT04116775` - Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.	Phase 2
Completed	`NCT03223727` - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Recruiting	`NCT04983095` - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer	Phase 3
Recruiting	`NCT04086290` - National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT03129139` - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04983628` - Molecular Profiling in Prostate Cancer
Active, not recruiting	`NCT03414437` - Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
Completed	`NCT02485691` - Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent	Phase 4
Completed	`NCT03693742` - MSG Use With 18F-DCFPyL PET/CT Imaging	N/A
Completed	`NCT01322490` - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer	Phase 3
Completed	`NCT03739684` - Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer	Phase 3